Patents by Inventor Gerard Johannes Platenburg

Gerard Johannes Platenburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10533171
    Abstract: The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 14, 2020
    Assignee: BioMarin Technologies B.V.
    Inventors: Judith Christina Theodora Van Deutekom, Josephus Johannes De Kimpe, Gerard Johannes Platenburg
  • Publication number: 20190292541
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Gerard Johannes Platenburg, Josephus Johannes De Kimpe, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus
  • Publication number: 20190177725
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20190119679
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20190112604
    Abstract: The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Patent number: 10246707
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?-GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: April 2, 2019
    Assignees: Biomarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Gerard Johannes Platenburg, Josephus Johannes de Kimpe, Judith Christina Theodora van Deutekom, Garrit-Jan Boudewijn van Ommen, Annemieke Aartsma-Rus
  • Publication number: 20180112214
    Abstract: The current invention provides for methods and medicaments that apply oligonucleotide molecules complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a method of treatment for cis-element repeat instability associated genetic disorders. The invention also pertains to modified oligonucleotides which can be applied in method of the invention to prevent the accumulation and/or translation of repeat expanded transcripts in cells.
    Type: Application
    Filed: December 27, 2017
    Publication date: April 26, 2018
    Inventors: Josephus Johannes De KIMPE, Gerard Johannes PLATENBURG, Derick Gert WANSINK
  • Patent number: 9890379
    Abstract: The current invention provides for methods and medicaments that apply oligonucleotide molecules complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a method of treatment for cis-element repeat instability associated genetic disorders. The invention also pertains to modified oligonucleotides which can be applied in method of the invention to prevent the accumulation and/or translation of repeat expanded transcripts in cells.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: February 13, 2018
    Assignee: BioMarin Technologies B.V.
    Inventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Derick Gert Wansink
  • Publication number: 20170204414
    Abstract: The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD.
    Type: Application
    Filed: March 24, 2017
    Publication date: July 20, 2017
    Inventors: Judith Christina Theodora Van DEUTEKOM, Josephus Johannes De KIMPE, Gerard Johannes PLATENBURG
  • Publication number: 20170107512
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 20, 2017
    Inventors: Josephus Johannes De KIMPE, Adriana Marie RUS, Gerard Johannes PLATENBURG, Judith Christina Theodora Van DEUTEKOM, Garrit-Jan Boudewijn Van OMMEN
  • Patent number: 9528109
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolated muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within the exon. The invention further relates to such molecule used in the method.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: December 27, 2016
    Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Josephus Johannes De Kimpe, Adriana Marie Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20160304864
    Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
    Type: Application
    Filed: January 7, 2016
    Publication date: October 20, 2016
    Inventors: Josephus Johannes De KIMPE, Gerard Johannes PLATENBURG, Judith Christina Theodora Van DEUTEKOM, Annemieke AARTSMA-RUS, Garrit-Jan Boudewijn Van OMMEN
  • Publication number: 20160264967
    Abstract: The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD.
    Type: Application
    Filed: May 31, 2016
    Publication date: September 15, 2016
    Inventors: Judith Christina Theodora Van DEUTEKOM, Josephus Johannes De KIMPE, Gerard Johannes PLATENBURG
  • Publication number: 20160053262
    Abstract: The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5?-GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
    Type: Application
    Filed: September 21, 2015
    Publication date: February 25, 2016
    Inventors: Gerard Johannes Platenburg, Josephus Johannes de Kimpe, Judith Christina Theodora van Deutekom, Garrit-Jan Boudewijn van Ommen, Annemieke Aartsma-Rus
  • Publication number: 20160053254
    Abstract: The current invention provides for methods and medicaments that apply oligonucleotide molecules complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a method of treatment for cis-element repeat instability associated genetic disorders. The invention also pertains to modified oligonucleotides which can be applied in method of the invention to prevent the accumulation and/or translation of repeat expanded transcripts in cells.
    Type: Application
    Filed: July 27, 2015
    Publication date: February 25, 2016
    Inventors: Josephus Johannes De KIMPE, Gerard Johannes PLATENBURG, Derick Gert WANSINK
  • Patent number: 9243245
    Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: January 26, 2016
    Assignees: Academisch Ziekenhuis Leiden, BioMarin Technologies B.V.
    Inventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Patent number: 9139828
    Abstract: The invention relates to oligonucleotides that bind to and induce skipping of exon 44 in the human dystrophin pre-mRNA, and methods of use.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: September 22, 2015
    Assignees: Prosensa Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Gerard Johannes Platenburg, Josephus Johannes de Kimpe, Judith Christina Theodora van Deutekom, Garrit-Jan Boudewijn van Ommen, Annemieke Aartsma-Rus
  • Publication number: 20150203849
    Abstract: The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD.
    Type: Application
    Filed: April 3, 2015
    Publication date: July 23, 2015
    Inventors: Judith Christina Theodora van Deutekom, Josephus Johannes de Kimpe, Gerard Johannes Platenburg
  • Publication number: 20150073037
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventors: Josephus Johannes De Kimpe, Annemieke Aartsma-Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20140221458
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Application
    Filed: March 7, 2014
    Publication date: August 7, 2014
    Applicants: Prosensa Technologies B.V., Academisch Ziekenhuis Leiden, Prosensa Holding B.V., Prosensa B.V.
    Inventors: Josephus Johannes De Kimpe, Annemieke Aartsma-Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen